Top Page
Global Bio-chem Technology Group Co. Ltd.
(0809)
Global Bio-chem Technology Group Co. Ltd. (0809) vs. iShares MSCI Hong Kong ETF (EWH)
Global Bio-chem Technology Group Co. Ltd. Business Overview & Revenue Model
Global Bio-chem Technology Group Co. Ltd. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.00B | 1.37B | 372.28M | 746.55M | 848.87M |
| Gross Profit | 218.68M | 43.64M | 34.60M | 48.35M | 74.10M |
| EBITDA | 16.85M | 4.69B | -469.06M | 785.63M | -1.39B |
| Net Income | 769.60M | 4.22B | -1.52B | -435.39M | -2.43B |
Balance Sheet | |||||
| Total Assets | 4.54B | 5.21B | 5.85B | 6.48B | 7.60B |
| Cash, Cash Equivalents and Short-Term Investments | 149.43M | 315.41M | 41.77M | 21.81M | 153.32M |
| Total Debt | 3.69B | 5.45B | 8.15B | 8.44B | 8.96B |
| Total Liabilities | 6.50B | 9.25B | 13.64B | 13.18B | 13.62B |
| Stockholders Equity | -1.95B | -4.04B | -7.54B | -6.52B | -5.86B |
Cash Flow | |||||
| Free Cash Flow | 76.04M | -94.24M | -94.19M | -501.02M | -43.02M |
| Operating Cash Flow | 76.04M | -50.46M | -88.01M | -475.21M | -26.19M |
| Investing Cash Flow | -535.00K | -14.37M | -413.00K | 392.59M | 120.09M |
| Financing Cash Flow | -76.06M | 165.81M | 109.75M | -48.66M | -25.87M |
Global Bio-chem Technology Group Co. Ltd. Technical Analysis
Global Bio-chem Technology Group Co. Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$1.07B | 8.93 | 5.08% | 8.88% | -1.19% | -9.05% | |
70 Outperform | HK$290.00M | 10.98 | 5.48% | 0.74% | 5.43% | -25.42% | |
65 Neutral | HK$1.18B | 2.61 | 10.38% | 4.76% | -6.58% | 16.23% | |
61 Neutral | $10.37B | 6.45 | -0.08% | 2.84% | 3.09% | -36.03% | |
56 Neutral | HK$920.69M | 29.21 | -0.99% | 14.04% | -4.42% | -157.03% | |
52 Neutral | HK$47.04M | ― | -12.63% | ― | 32.15% | -171.32% | |
48 Neutral | HK$819.48M | 1.10 | ― | 42.14% | -81.22% |
Global Bio-chem Technology Group Co. Ltd. Corporate Events
Global Bio-chem Technology Group Co. Ltd. reported its unaudited consolidated interim results for the six months ending June 30, 2025, showing a revenue increase to HK$1,185,983,000 from HK$898,541,000 in the same period of 2024. Despite the revenue growth, the company faced a total comprehensive loss of HK$251,895,000, attributed to high finance costs and other expenses, impacting its financial performance and indicating challenges in maintaining profitability.
Global Bio-chem Technology Group Co. Ltd. has announced an Extraordinary General Meeting (EGM) scheduled for September 18, 2025, in Hong Kong. The meeting aims to approve resolutions related to the company’s strategic plans, including the allotment and issuance of Consideration Shares under Specific Mandates. This move is expected to impact the company’s operational strategies and potentially influence its market positioning.
Global Bio-chem Technology Group Co. Ltd. has announced a delay in the dispatch of a circular related to its Suppliers Debt Restructuring Arrangement, which involves the issuance of Consideration Shares under a Specific Mandate. The circular, initially expected by 22 August 2025, will now be dispatched by 5 September 2025, as additional time is needed to finalize certain information. This delay may impact stakeholders awaiting detailed information on the debt restructuring and share issuance.
Global Bio-chem Technology Group Co. Ltd. has announced a board meeting scheduled for August 29, 2025, to discuss and approve the unaudited interim results for the first half of 2025 and to consider the payment of an interim dividend. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and potential shareholder returns.
Global Bio-chem Technology Group Co. Ltd. announced the successful closure of a public tender for an EPC Contract related to a Boiler Refurbishment Project. The contract, valued at a maximum of RMB129.1 million, was awarded to Northeast Electric and Liaoning Electric as joint bidders. This transaction is classified as a discloseable transaction under the Listing Rules due to its size, requiring notification and announcement. The project involves comprehensive engineering, procurement, and construction tasks, with incentives for early completion, potentially impacting the company’s operational efficiency and market positioning.
Global Bio-chem Technology Group Co. Ltd. has announced a delay in the dispatch of a circular related to its Suppliers Debt Restructuring Arrangement, which involves the issuance of Consideration Shares under a Specific Mandate. The delay is due to the need for additional time to prepare and finalize necessary information, with the new dispatch date set on or before August 22, 2025. This delay may impact the company’s operational timelines and stakeholder expectations, as the circular is crucial for informing shareholders about the upcoming Extraordinary General Meeting and related transactions.
Global Bio-chem Technology Group Co. Ltd. has announced a Suppliers Debt Restructuring Arrangement involving the re-acquisition of equity interest in Century Dacheng. This arrangement includes a debt-to-equity conversion and an equity-swap, resulting in Century Dacheng becoming an indirect wholly-owned subsidiary of the company again. The restructuring will be settled through the issuance of Consideration Shares, which will significantly affect the company’s share capital. The completion of this arrangement is subject to approval at an Extraordinary General Meeting (EGM), where shareholders will vote on the re-acquisition and the issuance of the Consideration Shares.
Global Bio-chem Technology Group Co. Ltd. has announced the completion of a Debt-to-Equity-Swap Agreement, resulting in Suppliers PRC LLPs holding a 28.98% equity interest in Century Dacheng. The company is progressing with its Suppliers Debt Restructuring Arrangement, expected to conclude by the end of 2025, pending necessary approvals. Concurrently, the company has reached settlement agreements with 33 remaining suppliers involving a significant debt discount, resulting in a projected net gain of no less than HK$17.0 million. These strategic financial maneuvers are aimed at stabilizing the company’s financial position and enhancing its operational capabilities.
Global Bio-chem Technology Group Co. Ltd. has announced a Suppliers Debt Restructuring Arrangement to address overdue payables amounting to RMB461.1 million, involving over 130 independent suppliers. This arrangement includes a debt-to-equity conversion and an equity swap, ultimately allowing suppliers to convert their debt into equity in a subsidiary, Century Dacheng, and then into shares of the company. This strategic move is expected to result in a net gain of no less than HK$190.0 million for the company, improving its financial standing and potentially enhancing shareholder value.